TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.

about

PharmGKB summary: pazopanib pathway, pharmacokinetics.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.

P2860

Q38693146-055C4C24-3631-4617-A2BA-14C2720B89E7 Q49888021-3BE1AD37-FFB1-4FD4-87C9-FF5F96E6C198

P2860

TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.

Item

http://www.wikidata.org/entity/Q50784573

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@en

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@nl

type

Item

label

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@en

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@nl

prefLabel

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@en

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@nl

P1476

TKI combination therapy: strat ...... Pgp- and BCRP-mediated efflux.

@en

P2093

Daryl J Murry

http://www.w3.org/2001/XMLSchema#string

Guohua An

http://www.w3.org/2001/XMLSchema#string

Ronilda D'Cunha

http://www.w3.org/2001/XMLSchema#string

SoHyun Bae

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Tyrosine kinase inhibitors: a clinical perspective.

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.

Clinical pharmacokinetics of tyrosine kinase inhibitors.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins

P304

397-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BDD.2022

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27418107

http://www.w3.org/2001/XMLSchema#string

TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.

about

P2860

P2860

TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698